Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Allergic Rhinitis AND Allergy AND Asthma

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44346   clinical trials with a EudraCT protocol, of which   7374   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    141 result(s) found for: Allergic Rhinitis AND Allergy AND Asthma. Displaying page 5 of 8.
    « Previous 1  2  3  4  5  6  7  8  Next»
    EudraCT Number: 2020-000446-34 Sponsor Protocol Number: MT-18 Start Date*: 2020-07-14
    Sponsor Name:ALK-Abelló A/S
    Full Title: A 28-day, single-armed, open-label trial to evaluate safety of the house dust mite (HDM) sublingual allergy immunotherapy (SLIT) tablet in adolescent subjects (12-17 years of age) with HDM allergic...
    Medical condition: Allergic rhinitis/rhinoconjunctivitis induced by house dust mite
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004870 10020419 House dust mite allergy LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SK (Completed) DE (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2014-003204-70 Sponsor Protocol Number: DOM-STA-2014-01 Start Date*: 2015-04-24
    Sponsor Name:Dr. Javier Domínguez Ortega
    Full Title: Pilot study on asthma control in patients with grass- pollen allergic rhinitis treated with 5 grass-pollen sublingual immunotherapy (Staloral®) vs placebo
    Medical condition: Respiratory Allergy: Asthma and allergic rhinitis due to grass pollen
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-001591-11 Sponsor Protocol Number: 3.4.11.049 Start Date*: 2012-12-21
    Sponsor Name:Erasmus MC
    Full Title: Symptomatic treatment of pollen related allergic rhinoconjunctivitis and the relation with asthma with children in the General practice
    Medical condition: Allergic Rhinitis Asthma
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-004262-34 Sponsor Protocol Number: MM09-SIT-023 Start Date*: 2020-04-28
    Sponsor Name:Inmunotek, S.L.
    Full Title: Randomized, placebo-controlled, prospective clinical trial of efficacy and safety for the treatment of rhinitis/rhinoconjunctivitis and asthma against a mixture of Dermatophagoides pteronyssinus an...
    Medical condition: House dust mites allergy
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004870 10020419 House dust mite allergy LLT
    20.0 100000004853 10001728 Allergic rhinoconjunctivitis LLT
    21.1 100000004855 10034382 Perennial allergic rhinitis LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-000870-79 Sponsor Protocol Number: 101-PG-PSC-186 Start Date*: 2012-02-17
    Sponsor Name:Laboratorios LETI, S.L.U.
    Full Title: Prospective study to evaluate the safety of a 4-month treatment with Depigoid® Dermatophagoides pteronyssinus or 50% Dermatophagoides pteronyssinus / 50% Dermatophagoides farinae (500 DPP/ml) in pa...
    Medical condition: Allergic rhinitis or rhinoconjunctivitis with or without mild persistent or intermittent asthma, to Dermatophagoides pteronyssinus or Dermatophagoides pteronyssinus and Dermatophagoides farinae.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021428 - Immune system disorders 10020419 House dust mite allergy LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-006261-81 Sponsor Protocol Number: PM/0028 Start Date*: 2009-06-24
    Sponsor Name:HAL Allergy
    Full Title: Dose Tolerability Study with High Dose PURETHAL Mites in Allergic Rhinitis / Rhinoconjunctivitis Patients. An open study to assess tolerability, safety and short-term efficacy of high dose PURETHA...
    Medical condition: Allergic (IgE-mediated) rhinitis / rhinoconjunctivitis triggered by house dust mites.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001725 Allergic rhinitis due to other allergen LLT
    9.1 10053713 Allergenic desensitisation procedure LLT
    9.1 10053741 Allergenic desensitization procedure LLT
    9.1 10001709 Allergic conjunctivitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-000025-35 Sponsor Protocol Number: Al0204AV Start Date*: 2005-04-05
    Sponsor Name:Allergopharma Joachim Ganzer KG
    Full Title: A multicentre randomised placebo-controlled double-blind clinical trial for evaluation of safety and efficacy of specific immunotherapy with an aluminium hydroxide-adsorbed allergoid preparation of...
    Medical condition: IgE-mediated allergic diseases including allergic rhinitis/rhinoconjunctivitis, allergic bronchial asthma (GINA I and II) triggered by birch pollen allergens
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) FI (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2018-001339-33 Sponsor Protocol Number: SCITVITD3 Start Date*: 2018-07-05
    Sponsor Name:Academisch medisch centrum Amsterdam
    Full Title: A randomized, double-blind, placebo-controlled, study to determine the added value of vitamin D3 to treatment with subcutaneous immunotherapy in patients with moderate to severe allergic rhinitis/ ...
    Medical condition: subcutaneous immunotherapy in allergic rhinitis (AR) patients with allergies to birchpollen
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-001733-13 Sponsor Protocol Number: CP007 Start Date*: 2012-10-04
    Sponsor Name:Circassia Limited
    Full Title: A Double Blind, Randomised, Placebo Controlled Multi-Centre Field Study to Assess the Efficacy and Safety of Cat-PAD Peptide Immunotherapy in Cat Allergic Subjects
    Medical condition: Treatment of cat allergen induced rhinoconjunctivitis in patients with clinically relevant symptoms
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004855 10034382 Perennial allergic rhinitis LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: PL (Completed) BE (Completed) CZ (Completed) DE (Completed) HU (Completed) SK (Completed) LT (Prematurely Ended) LV (Prematurely Ended) EE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-000279-15 Sponsor Protocol Number: CP009 Start Date*: 2014-07-03
    Sponsor Name:Circassia Limited
    Full Title: A Multi-Centre, Single-Blind Study to Assess the Safety of Cat-PAD in Cat Allergic Paediatric Subjects.
    Medical condition: Treatment of cat-allergen induced rhinoconjunctivitis in paediatric subjects with clinically relevant symptoms
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004855 10034382 Perennial allergic rhinitis LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2021-002089-42 Sponsor Protocol Number: R1908-1909-ALG-2102 Start Date*: 2021-11-18
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Study in Cat-Allergic Patients with Allergic Rhinitis Who Live with a Cat to Assess the Efficacy and Safety of Anti-Fel d 1 Antibodies during Natural ...
    Medical condition: Allergic Rhino conjunctivitis due to Cat Allergy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10001708 Allergic conditions HLGT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Prematurely Ended) FR (Prematurely Ended) PL (Completed)
    Trial results: View results
    EudraCT Number: 2012-000414-11 Sponsor Protocol Number: 603-PG-PSC-191 Start Date*: 2012-08-31
    Sponsor Name:LETI Pharma GmbH
    Full Title: Multicenter, placebo-controlled, long-term study of Depigoid Birch 5000 in adults and adolescents with allergic rhinitis and/or rhinoconjunctivitis with or without intermittent asthma
    Medical condition: Seasonal allergic rhinitis and/or rhinoconjunctivitis with or without intermittent asthma due to birch pollen allergy
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004870 10066093 Birch pollen allergy LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) LT (Completed) CZ (Completed) FI (Completed) PL (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2006-000359-16 Sponsor Protocol Number: VD-3 Start Date*: 2007-04-16
    Sponsor Name:Ove Bäck, Dept Dermatology, University Hospital, Lund, Sweden
    Full Title: Vitamin D and atopic allergy
    Medical condition: Cumulative incidence of atopic allergy specified as atopic dermatitis, allergic asthma, and allergic rhinitis. Since IMP is a food supplement to protect from rickets we are looking at clinical sym...
    Disease:
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-004806-40 Sponsor Protocol Number: MEIN/15/Bil-ARC/001 Start Date*: 2016-03-29
    Sponsor Name:Menarini International Operations Luxembourg S.A.
    Full Title: Bilastine and Montelukast in patients with seasonal allergic rhinoconjunctivitis and asthma: Efficacy of concomitant administration - the SKY study; Acronym: SKY
    Medical condition: Seasonal allergic rhinoconjunctivitis and asthma
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SK (Completed) CZ (Completed) PL (Completed) LV (Completed) HR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-002911-33 Sponsor Protocol Number: ABT-gpASIT011 Start Date*: 2018-12-18
    Sponsor Name:ASIT biotech S.A.
    Full Title: A multicentre, international, randomised, double-blind, placebo controlled study to demonstrate the clinical efficacy and safety of subcutaneous immunotherapy with gpASIT+™ in patients with grass p...
    Medical condition: Treatment of seasonal grass pollen-induced rhinoconjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004870 10019170 Hay fever LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) CZ (Prematurely Ended) HU (Prematurely Ended) BE (Prematurely Ended) PL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-001795-20 Sponsor Protocol Number: MT-02 Start Date*: 2006-06-29
    Sponsor Name:ALK-Abelló A/S
    Full Title: A phase II-III trial assessing the efficacy and safety of three doses of the ALK HDM tablet in house dust mite allergic subjects
    Medical condition: IgE mediated House dust mite induced mild to moderate asthma and mild to severe allergic rhinitis.
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed) ES (Completed) DK (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-005868-10 Sponsor Protocol Number: 6043-PG-PSC-153 Start Date*: 2007-07-24
    Sponsor Name:Laboratorios LETI S.L.
    Full Title: Ensayo clínico, multicéntrico, aleatorizado, doble ciego controlado con placebo, de inmunoterapia subcutánea con extracto despigmentado y polimerizado de polen de Phleum pratense en pacientes con h...
    Medical condition: Rinoconjuntivitis moderada-severa (con o sin asma episódico) inducida por hipersensibilidad frente al polen de gramíneas.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10039097 Rhinoconjunctivitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed) HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-000172-26 Sponsor Protocol Number: 1301-PG-PSC-203 Start Date*: 2014-06-26
    Sponsor Name:Laboratorios LETI S.L.U
    Full Title: A multicentre, open label, phase IIb clinical trial to evaluate safety, tolerability and efficacy of the depigmented modified allergen extract of two mites mixes at 200 DPP/ml (DP/MG/14-1 Dermatoph...
    Medical condition: Allergic rhinitis or rihinoconjuntivitis, with controlled allergic asthma due to D. pteronyssinus and Blomia tropicalis or Lepidoglyphus destructor sensitization.
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004870 10020419 House dust mite allergy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2011-002317-10 Sponsor Protocol Number: SC-31A Start Date*: 2019-04-17
    Sponsor Name:ROXALL Medizin GmbH
    Full Title: Phase II study to assess the tolerability, safety and efficacy of subcutaneous cluster-immunotherapy in patients suffering from house dust mite allergy
    Medical condition: Allergic rhinitis / rhino-conjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10001728 Allergic rhinoconjunctivitis LLT
    20.0 100000004870 10020419 House dust mite allergy LLT
    21.1 100000004855 10034382 Perennial allergic rhinitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-006251-11 Sponsor Protocol Number: HLS05/2011 Start Date*: 2012-03-19
    Sponsor Name:AZIENDA OSPEDALIERA L. SACCO (A.O. DI RILIEVO NAZIONALE)
    Full Title: Pilot clinical trial, controlled and randomized, Phase III, to evaluate security and efficacy of oral specific immunotherapy in HIV infected patients who suffer from grass pollen allergy.
    Medical condition: HIV+ subjects with grass pollen allergy.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021428 - Immune system disorders 10001708 Allergic conditions HLGT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Jul 03 02:36:45 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA